-
Disease Gene Prioritization With Quantum Walks
Authors:
Harto Saarinen,
Mark Goldsmith,
Rui-Sheng Wang,
Joseph Loscalzo,
Sabrina Maniscalco
Abstract:
Disease gene prioritization assigns scores to genes or proteins according to their likely relevance for a given disease based on a provided set of seed genes. Here, we describe a new algorithm for disease gene prioritization based on continuous-time quantum walks using the adjacency matrix of a protein-protein interaction (PPI) network. Our algorithm can be seen as a quantum version of a previous…
▽ More
Disease gene prioritization assigns scores to genes or proteins according to their likely relevance for a given disease based on a provided set of seed genes. Here, we describe a new algorithm for disease gene prioritization based on continuous-time quantum walks using the adjacency matrix of a protein-protein interaction (PPI) network. Our algorithm can be seen as a quantum version of a previous method known as the diffusion kernel, but, importantly, has higher performance in predicting disease genes, and also permits the encoding of seed node self-loops into the underlying Hamiltonian, which offers yet another boost in performance. We demonstrate the success of our proposed method by comparing it to several well-known gene prioritization methods on three disease sets, across seven different PPI networks. In order to compare these methods, we use cross-validation and examine the mean reciprocal ranks and recall values. We further validate our method by performing an enrichment analysis of the predicted genes for coronary artery disease. We also investigate the impact of adding self-loops to the seeds, and argue that they allow the quantum walker to remain more local to low-degree seed nodes.
△ Less
Submitted 9 November, 2023;
originally announced November 2023.
-
Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing
Authors:
Andreas Maier,
Michael Hartung,
Mark Abovsky,
Klaudia Adamowicz,
Gary D. Bader,
Sylvie Baier,
David B. Blumenthal,
Jing Chen,
Maria L. Elkjaer,
Carlos Garcia-Hernandez,
Mohamed Helmy,
Markus Hoffmann,
Igor Jurisica,
Max Kotlyar,
Olga Lazareva,
Hagai Levi,
Markus List,
Sebastian Lobentanzer,
Joseph Loscalzo,
Noel Malod-Dognin,
Quirin Manz,
Julian Matschinske,
Miles Mee,
Mhaned Oubounyt,
Alexander R. Pico
, et al. (14 additional authors not shown)
Abstract:
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining…
▽ More
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.
△ Less
Submitted 4 July, 2023; v1 submitted 24 May, 2023;
originally announced May 2023.
-
Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19
Authors:
Deisy Morselli Gysi,
Ítalo Do Valle,
Marinka Zitnik,
Asher Ameli,
Xiao Gan,
Onur Varol,
Susan Dina Ghiassian,
JJ Patten,
Robert Davey,
Joseph Loscalzo,
Albert-László Barabási
Abstract:
The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and di…
▽ More
The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and disease genes. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs that had been experimentally screened in VeroE6 cells, and the list of drugs under clinical trial, that capture the medical community's assessment of drugs with potential COVID-19 efficacy. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics. This prompted us to develop a multimodal approach that fuses the predictions of all algorithms, showing that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We find that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these drugs rely on network-based actions that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.
△ Less
Submitted 9 August, 2020; v1 submitted 15 April, 2020;
originally announced April 2020.
